The global sarcoma drugs market was valued at $1,127 million in 2021, and is projected to reach $2,497.1 million by 2031, growing at a CAGR of 8.3% from 2022 to 2031. Sarcoma is a form of cancer that develops in soft tissues such as cartilage, fat, muscle, blood vessels, fibrous tissue, and other connective or supportive tissues as well as in bone. Based on where the cancer develops, there are various varieties of sarcoma. For instance, rhabdomyosarcoma develops in muscles, liposarcoma develops in fat, and osteosarcoma develops in bones. The type and grade of the cancer determines course of treatment and prognosis (how abnormal the cancer cells look under a microscope and how quickly the cancer is likely to grow and spread). Both children and adults can develop sarcoma. Chemotherapy and targeted therapy are two treatment options available for sarcoma treatment.
The sarcoma drugs market is driven by rise in prevalence of cancer, technological advancements in development of sarcoma drugs, and rise in number of product launches and approvals for sarcoma drugs. For instance, according to the World Cancer Research Fund International, it was reported that 18,094,716 cancer cases were diagnosed across the globe. In addition, rise in prevalence of soft tissue sarcoma fuels demand for sarcoma drugs for treatment purpose. Thus, this factor is anticipated to drive growth of the sarcoma drugs market. For instance, according to the American Cancer Society, in 2022, it was estimated that about 13,190 new soft tissue sarcomas will be diagnosed, among them 7,590 in males and 5,600 in females in the U. S. in 2022. As per the same source, it was estimated that around 5,130 people (2,740 males and 2,390 females) are expected to die of soft tissue sarcomas.
The global sarcoma drugs market is predicted to develop as more patients battle soft tissue sarcoma, which causes increase in shift of consumer preference toward medicinal treatment over surgical procedures. The use of chemotherapy and targeted therapy supported by a number of advantages, including quicker healing, lower morbidity and mortality, and shorter hospital stays.
Geriatric population is more susceptible to chronic diseases such as cancer. Rise in number of geriatric populations increases demand of sarcoma drugs for cancer treatment. Thus, this factor contributes toward growth of the sarcoma drugs market. In addition, governments globally have increased the expenditure on the healthcare sector. For instance, according to the Centers for Medicare & Medicaid Services, the U. S. health care spending grew by 9.7% from 2019 to 2020, reaching $4.1 trillion ($12,530 per person). Similarly, as per the Office for National Statistics, total healthcare expenditure in the UK accounted for 12.8% of the gross domestic product (GDP) in 2020, compared to 10.2% in 2019. Furthermore, it has been estimated that approximately 30% of the healthcare expenditure is used in upgrading the healthcare infrastructure, especially medical equipment used at public health centers (hospitals). Hence, this rise in healthcare expenditure across the globe is expected to fuel demand for sarcoma drugs in different disease treatments, which boosts the market growth.
On the other hand, high cost associated with sarcoma drugs and side effects of chemotherapy hinder the market growth.
The global sarcoma drugs market is segmented on the basis of disease indication, treatment, end user, and region. On the basis of type the market is segmented into malignant bone tumors and soft tissue sarcoma. The soft tissue sarcoma segment is further sub-segmented into dermatofibrosarcoma, leiomyosarcoma, synovial cell sarcoma, rhabdomyosarcoma, and others. On the basis of treatment, the market is segmented into chemotherapy and targeted drug therapy. By end user, it is bifurcated into hospitals & clinics and cancer research centers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global sarcoma drugs market include Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Hoffmann-La Roche AG., Daiichi Sankyo Company, Limited., AgonOX, Inc. and Eisai Co., Ltd.
The sarcoma drugs market is driven by rise in prevalence of cancer, technological advancements in development of sarcoma drugs, and rise in number of product launches and approvals for sarcoma drugs. For instance, according to the World Cancer Research Fund International, it was reported that 18,094,716 cancer cases were diagnosed across the globe. In addition, rise in prevalence of soft tissue sarcoma fuels demand for sarcoma drugs for treatment purpose. Thus, this factor is anticipated to drive growth of the sarcoma drugs market. For instance, according to the American Cancer Society, in 2022, it was estimated that about 13,190 new soft tissue sarcomas will be diagnosed, among them 7,590 in males and 5,600 in females in the U. S. in 2022. As per the same source, it was estimated that around 5,130 people (2,740 males and 2,390 females) are expected to die of soft tissue sarcomas.
The global sarcoma drugs market is predicted to develop as more patients battle soft tissue sarcoma, which causes increase in shift of consumer preference toward medicinal treatment over surgical procedures. The use of chemotherapy and targeted therapy supported by a number of advantages, including quicker healing, lower morbidity and mortality, and shorter hospital stays.
Geriatric population is more susceptible to chronic diseases such as cancer. Rise in number of geriatric populations increases demand of sarcoma drugs for cancer treatment. Thus, this factor contributes toward growth of the sarcoma drugs market. In addition, governments globally have increased the expenditure on the healthcare sector. For instance, according to the Centers for Medicare & Medicaid Services, the U. S. health care spending grew by 9.7% from 2019 to 2020, reaching $4.1 trillion ($12,530 per person). Similarly, as per the Office for National Statistics, total healthcare expenditure in the UK accounted for 12.8% of the gross domestic product (GDP) in 2020, compared to 10.2% in 2019. Furthermore, it has been estimated that approximately 30% of the healthcare expenditure is used in upgrading the healthcare infrastructure, especially medical equipment used at public health centers (hospitals). Hence, this rise in healthcare expenditure across the globe is expected to fuel demand for sarcoma drugs in different disease treatments, which boosts the market growth.
On the other hand, high cost associated with sarcoma drugs and side effects of chemotherapy hinder the market growth.
The global sarcoma drugs market is segmented on the basis of disease indication, treatment, end user, and region. On the basis of type the market is segmented into malignant bone tumors and soft tissue sarcoma. The soft tissue sarcoma segment is further sub-segmented into dermatofibrosarcoma, leiomyosarcoma, synovial cell sarcoma, rhabdomyosarcoma, and others. On the basis of treatment, the market is segmented into chemotherapy and targeted drug therapy. By end user, it is bifurcated into hospitals & clinics and cancer research centers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global sarcoma drugs market include Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Hoffmann-La Roche AG., Daiichi Sankyo Company, Limited., AgonOX, Inc. and Eisai Co., Ltd.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the sarcoma drugs market analysis from 2021 to 2031 to identify the prevailing sarcoma drugs market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the sarcoma drugs market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global sarcoma drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Disease Indication
- Malignant bone tumors
- Soft tissue sarcoma
- Type
- Dermatofibro sarcoma
- Leiomyosarcoma
- Synovial cell sarcoma
- Rhabdomyo sarcoma
- Others
By Treatment
- Chemotherapy
- Targeted drug therapy
By End User
- Hospital and clinics
- Cancer research center
By Region
- North America
- U. S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Baxter Healthcare Corporation
- BRISTOL-MYERS SQUIBB COMPANY
- Daiichi Sankyo Company, Limited
- AgonOX, Inc.
- Eisai Co., Ltd.
- GlaxoSmithKline, plc.
- Hoffmann-La Roche AG.
- Johnson and Johnson
- MERCK & CO., INC.
- Novartis AG
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
CHAPTER 4: SARCOMA DRUGS MARKET, BY DISEASE INDICATION
4.1 Overview
4.1.1 Market size and forecast
4.2 Malignant bone tumors
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Soft tissue sarcoma
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.3.4 Soft tissue sarcoma Sarcoma Drugs Market by Type
4.3.4.1 Dermatofibro sarcoma Market size and forecast, by region
4.3.4.2 Leiomyosarcoma Market size and forecast, by region
4.3.4.3 Synovial cell sarcoma Market size and forecast, by region
4.3.4.4 Rhabdomyo sarcoma Market size and forecast, by region
4.3.4.5 Others Market size and forecast, by region
CHAPTER 5: SARCOMA DRUGS MARKET, BY TREATMENT
5.1 Overview
5.1.1 Market size and forecast
5.2 Chemotherapy
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Targeted drug therapy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: SARCOMA DRUGS MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital and clinics
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Cancer research center
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: SARCOMA DRUGS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Disease Indication
7.2.2.1 North America Soft tissue sarcoma Sarcoma Drugs Market by Type
7.2.3 North America Market size and forecast, by Treatment
7.2.4 North America Market size and forecast, by End User
7.2.5 North America Market size and forecast, by country
7.2.5.1 U. S.
7.2.5.1.1 Market size and forecast, by Disease Indication
7.2.5.1.2 Market size and forecast, by Treatment
7.2.5.1.3 Market size and forecast, by End User
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Disease Indication
7.2.5.2.2 Market size and forecast, by Treatment
7.2.5.2.3 Market size and forecast, by End User
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Disease Indication
7.2.5.3.2 Market size and forecast, by Treatment
7.2.5.3.3 Market size and forecast, by End User
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Disease Indication
7.3.2.1 Europe Soft tissue sarcoma Sarcoma Drugs Market by Type
7.3.3 Europe Market size and forecast, by Treatment
7.3.4 Europe Market size and forecast, by End User
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Disease Indication
7.3.5.1.2 Market size and forecast, by Treatment
7.3.5.1.3 Market size and forecast, by End User
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Disease Indication
7.3.5.2.2 Market size and forecast, by Treatment
7.3.5.2.3 Market size and forecast, by End User
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Disease Indication
7.3.5.3.2 Market size and forecast, by Treatment
7.3.5.3.3 Market size and forecast, by End User
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Disease Indication
7.3.5.4.2 Market size and forecast, by Treatment
7.3.5.4.3 Market size and forecast, by End User
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Disease Indication
7.3.5.5.2 Market size and forecast, by Treatment
7.3.5.5.3 Market size and forecast, by End User
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Disease Indication
7.3.5.6.2 Market size and forecast, by Treatment
7.3.5.6.3 Market size and forecast, by End User
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Disease Indication
7.4.2.1 Asia-Pacific Soft tissue sarcoma Sarcoma Drugs Market by Type
7.4.3 Asia-Pacific Market size and forecast, by Treatment
7.4.4 Asia-Pacific Market size and forecast, by End User
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 China
7.4.5.1.1 Market size and forecast, by Disease Indication
7.4.5.1.2 Market size and forecast, by Treatment
7.4.5.1.3 Market size and forecast, by End User
7.4.5.2 Japan
7.4.5.2.1 Market size and forecast, by Disease Indication
7.4.5.2.2 Market size and forecast, by Treatment
7.4.5.2.3 Market size and forecast, by End User
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Disease Indication
7.4.5.3.2 Market size and forecast, by Treatment
7.4.5.3.3 Market size and forecast, by End User
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Disease Indication
7.4.5.4.2 Market size and forecast, by Treatment
7.4.5.4.3 Market size and forecast, by End User
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Disease Indication
7.4.5.5.2 Market size and forecast, by Treatment
7.4.5.5.3 Market size and forecast, by End User
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Disease Indication
7.4.5.6.2 Market size and forecast, by Treatment
7.4.5.6.3 Market size and forecast, by End User
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Disease Indication
7.5.2.1 LAMEA Soft tissue sarcoma Sarcoma Drugs Market by Type
7.5.3 LAMEA Market size and forecast, by Treatment
7.5.4 LAMEA Market size and forecast, by End User
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Disease Indication
7.5.5.1.2 Market size and forecast, by Treatment
7.5.5.1.3 Market size and forecast, by End User
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Disease Indication
7.5.5.2.2 Market size and forecast, by Treatment
7.5.5.2.3 Market size and forecast, by End User
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Disease Indication
7.5.5.3.2 Market size and forecast, by Treatment
7.5.5.3.3 Market size and forecast, by End User
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Disease Indication
7.5.5.4.2 Market size and forecast, by Treatment
7.5.5.4.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Players
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Baxter Healthcare Corporation
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 BRISTOL-MYERS SQUIBB COMPANY
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Daiichi Sankyo Company, Limited
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 AgonOX, Inc.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Eisai Co., Ltd.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 GlaxoSmithKline, plc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Hoffmann-La Roche AG.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Johnson and Johnson
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 MERCK & CO., INC.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Novartis AG
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
Executive Summary
According to this report, titled, 'Sarcoma Drugs Market,' the global sarcoma drugs market size was valued at $1,127.0 million in 2021, and is projected to reach $2,497.1 million by 2031, registering a CAGR of 8.3% from 2022 to 2031.Sarcoma is a form of cancer that can appear anywhere on the body. A large range of tumors that start in the bones and soft tissues are collectively referred to as sarcomas, commonly known as soft tissue sarcomas. The tissues that join, encircle, and support other body structures are where soft tissue sarcomas develop. This comprises muscles, fat, blood vessels, nerves, tendons, and joint lining. Sarcomas come in over 70 different varieties. The type, location, and other aspects of sarcoma all affect how they are treated.
Factors that can increase the risk of sarcoma drugs market size includes inherited syndromes. Syndromes that increase risk of sarcoma include familial retinoblastoma and neurofibromatosis type 1. Radiation treatment for cancer increases the risk of developing a sarcoma later. Lymphedema is swelling caused by a backup of lymph fluid that occurs when lymphatic system is blocked or damaged. It increases the risk of a type of sarcoma called angiosarcoma. Certain chemicals, such as some industrial chemicals and herbicides, can increase the risk of sarcoma that affects the liver. In addition, the virus called human herpesvirus 8 can increase the risk of a type of sarcoma called Kaposi's sarcoma in people with weakened immune systems, and impact sarcoma drugs market analysis. Moreover, rise in the awareness among people regarding availability of healthcare services, rise in number of sarcoma drugs industry and increase in the number of diagnostic centers anticipated to fuel the sarcoma drugs market trends.
On the basis of disease indication, the sarcoma drugs market share is classified into malignant bone tumors and soft tissue sarcoma. The soft tissue sarcoma segment dominated the market in 2021, and is expected to continue this trend during the forecast period, owing to increase in awareness among people regarding soft tissue sarcoma and rise in prevalence of soft tissue sarcoma.
On the basis of treatment, it is classified into chemotherapy, targeted drug therapy and others. The chemotherapy segment dominated the market in 2021, and is expected to continue this trend during the sarcoma drugs market forecast period, owing to increase in the awareness among the people regarding chemotherapy and rise in number of product launch for chemotherapy.
On the basis of end user, the market is classified into hospitals & clinics and cancer research centers. The Hospitals & clinics segment dominated the market in 2021, and is expected to continue this trend during the forecast period, owing to rise in expenditure by governments to develop healthcare sector.
North America accounted for a majority of the global sarcoma drugs market share in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to increase in the number of research activities, technological advancement in the healthcare sector and rise in the prevalence of soft tissue sarcoma. Asia-Pacific is anticipated to witness lucrative growth, owing to rise in expenditure by government organizations to develop the healthcare sector, increase in prevalence of cancer, and rise in number of sarcoma drugs industry who manufacture sarcoma drugs.
The COVID-19 outbreak is anticipated to have a negative impact on growth of the global sarcoma drugs market. For instance, according to JCO Global Oncology, an American Society of Clinical Oncology Journal, it was reported that delay and disruptions most investigated included reduction in routine activity of cancer services and number of cancer surgeries. There is delay, reschedule, or cancellation of outpatient visits. Interruptions and disruptions largely affected facilities and supply chain.
Key Findings of The Study
By disease indication, the soft tissue sarcoma segment was the highest contributor to the market in 2021.By treatment, the chemotherapy segment was the highest contributor to the market in 2021.
By end user, the Hospitals & clinics segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
By region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Baxter Healthcare Corporation
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company, Limited
- Agonox, Inc.
- Eisai Co. Ltd.
- GlaxoSmithKline, PLC.
- Hoffmann-La Roche AG.
- Johnson and Johnson
- Merck & Co. Inc.
- Novartis AG
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 220 |
| Published | October 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 1127 million |
| Forecasted Market Value ( USD | $ 2497.1 million |
| Compound Annual Growth Rate | 8.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
